Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

PRIME: PrEP Intervention for people who Inject MEthamphetamine

Award Number: R01DA051850
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

PRIME: PrEP Intervention for people who Inject MEthamphetamine - Project Summary/Abstract Notwithstanding a substantial effort of “getting to zero”, new HIV infections among people who inject drugs are increasing. Methamphetamine is a primary driver of that increase, as methamphetamine use has been extensively demonstrated to increase both sexual and injection-related HIV transmission. Methamphetamine use is also associated with poor medication adherence, such that people with HIV who use methamphetamine are less likely to be virally suppressed. The most powerful tool for prevention of HIV available today, in addition to aggressive treatment of people living with HIV to ensure viral suppression, is pre-exposure prophylaxis (PrEP) with emtricitabine plus a tenofovir product (e.g. FTC/TAF). PrEP has been extensively demonstrated to reduce HIV infection when taken in sufficient amounts, generally defined as ≥4 doses per week. The Centers for Disease Control and other health agencies recommend PrEP for people who inject drugs, yet there has been precious little attention to this population in PrEP clinical trials, implementation studies, and demonstration projects. Two major reasons for this lack of attention are (1) that syringe access programs, where available, are powerful tools to lower HIV transmission by injection, and (2) that people who inject drugs – and in particular people who use methamphetamine – are likely to struggle with medication adherence. In the context of expanding methamphetamine use – as the next wave of the opioid crisis – and a national effort to eliminate HIV transmission, syringe access programs are unlikely to be sufficient to prevent the remaining infections that occur. In this study, “PrEP Intervention for people who Inject Methamphetamine” (PRIME), we propose to address the second concern by testing a combined adherence intervention. PRIME is a two-arm trial comparing standardized counseling to video directly-observed treatment with real-time contingency management (VDOT-CM) for adherence to once-daily emtricitabine/tenofovir alafenamide (FTC/TAF) PrEP among people who inject methamphetamine. We will randomize 140 adults who inject methamphetamine, are HIV-negative, and have recently engaged in HIV risk behaviors to VDOT-CM or counseling alone for 24 weeks. Both groups will receive PrEP and counseling to support PrEP adherence; the intervention condition will also receive a mobile phone app that video records daily PrEP use and a nominal contingency management incentive to complete the observed PrEP dosing. We will compare adherence to PrEP in both arms by testing dried blood spots for tenofovir disphosphate (TFV-DP) levels of ≥ 950 fmol/punch, corresponding to ≥4 doses per week. We will assess acceptability of PrEP in this population through qualitative interviews and survey items. Finally, we will compare injection and sexual risk behaviors prior to PrEP to those while on PrEP, to evaluate for risk compensation. Study results will provide critical data for intensive adherence support for PrEP among people who inject methamphetamine, a very high risk population for HIV transmission.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = $0 )
2027	2024	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	5	10/30/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $738,862 )
2024	2024	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	5	6/25/2024	NON-COMPETING CONTINUATION	$738,862
2024	2023	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	001	4	9/13/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $738,862

Issue Date FY: 2023 ( Subtotal = $828,852 )
2023	2023	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	4	6/28/2023	NON-COMPETING CONTINUATION	$828,852
														Subtotal = $828,852

Issue Date FY: 2022 ( Subtotal = $828,852 )
2022	2022	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N STE 450	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	3	6/29/2022	NON-COMPETING CONTINUATION	$828,852
														Subtotal = $828,852

Issue Date FY: 2021 ( Subtotal = $828,852 )
2021	2021	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N STE 450	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	2	6/8/2021	NON-COMPETING CONTINUATION	$828,852
														Subtotal = $828,852

Issue Date FY: 2020 ( Subtotal = $786,761 )
2020	2020	PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.	13300 CROSSROADS PKWY N STE 450	CITY OF INDUSTRY	CA	91746	LOS ANGELES	USA	Drug Use and Addiction Research Programs	000	1	7/24/2020	NEW	$786,761
														Subtotal = $786,761

Grand Total All Awards = $4,012,179

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PRIME: PrEP Intervention for people who Inject MEthamphetamine

Award Number: R01DA051850

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer